Mark Bartholomä
Hat mitgewirkt an:
-
Synthese und Komplexbildung neuartiger, multidentater Derivate von 1,3,5-Triamino-1,3,5-tridesoxy-cis-inosit
-
A Structure‐Activity Relationship Study of Bimodal BODIPY‐Labeled PSMA‐Targeting Bioconjugates
-
Change in total lesion PSMA (TLP) during [177Lu]Lu-PSMA-617 radioligand therapy predicts overall survival in patients with mCRPC: monocentric evaluation of a prospective registry
-
Efficacy and safety of rechallenge [177Lu]Lu-PSMA-617 RLT after initial partial remission in patients with mCRPC: evaluation of a prospective registry (REALITY study)